To compare the safety and efficacy of ABT-494 30 mg once daily (QD) and 15 mg QD versus placebo on a background of csDMARD(s) for the treatment of signs and symptoms of rheumatoid arthritis (RA) in bDMARD-inadequate response (bDMARD-IR) or bDMARD-intolerant subjects with moderately to severely active RA.
Chief Investigator: Dr Neil McKay
Number and location of participating sites (by region/ country): International multicentre trial approx. 300
EudraCT number: 2015-003335-35
Funder: AbbVie
Start and End date of grant award: Aug 2016 - Aug 2018
Current Status: recruiting
Contact details / Sponsor: AbbVie
Dept. R477, Bldg. AP4, 1 North Waukegan Road, North Chicago, IL 60064
ECTU involvement: Clinical support – research nurses